AgomAb Therapeutics NV
AGMB scores 0.0 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -29.2 points significantly impact the ranking. Without these adjustments, AGMB would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| AGMB | 0.0 | N/A | N/A | 0.0% | $755M |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $20.2B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $18.1B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $2.9B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $14.0B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $125.2B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.3B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.8B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $210.2B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $48.0B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $81.3B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $177.8B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $8.0B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | — |
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Not enough price history to compute reliable entry and exit zones for this stock.
| Metric | Q4 2024 |
|---|---|
| Revenue | $0 |
| Gross Profit | $0 |
| Operating Income | $-12M |
| Net Income | $-12M |
| EPS (Diluted) | $0.00 |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
This stock has limited trading volume and/or float. Institutional investors may face difficulty entering or exiting positions without significant price impact. A post-hoc penalty has been applied to the composite score (this is not a backtested model factor — it is a practical tradability overlay).
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.